
Kali Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1703047/publications.pdf Version: 2024-02-01



Κλιι Ζμομ

#	Article	IF	CITATIONS
1	Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults. Digestive Diseases and Sciences, 2022, 67, 3340-3355.	1.1	6
2	Diverging Incidence Trends for Hepatocellular Carcinoma in Rural and Urban Settings in the United States. Clinical Gastroenterology and Hepatology, 2022, 20, 1180-1185.e2.	2.4	6
3	Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELDâ€Na allocation. Clinical Transplantation, 2022, 36, e14527.	0.8	5
4	Lower Alphaâ€Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma. Liver Transplantation, 2022, 28, 763-773.	1.3	4
5	Geographic hotspot detection for late-stage hepatocellular carcinoma: novel approach to cancer control. Cancer Causes and Control, 2022, 33, 701-710.	0.8	5
6	Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir—a "knockâ€outâ€is yet to be delivered. Alimentary Pharmacology and Therapeutics, 2022, 55, 1342-1343.	1.9	1
7	The Updated US Preventive Services Task Force Hepatitis B Screening Recommendations—Staying Committed. JAMA Internal Medicine, 2021, 181, 310.	2.6	0
8	No Foul Play for Transjugular Intrahepatic Portosystemic Shunts in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2021, 27, 1680-1681.	1.3	1
9	Potential association between public medical insurance, waitlist mortality, and utilization of living donor liver transplantation: An analysis of the Scientific Registry of Transplant Recipients. Clinical Transplantation, 2021, 35, e14418.	0.8	2
10	Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. Cancers, 2021, 13, 3476.	1.7	13
11	Discussion on "Causal mediation of semicompeting risks―by Yenâ€Tsung Huang. Biometrics, 2021, 77, 1165-1169.	0.8	3
12	Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectrum, 2021, 5, pkaa100.	1.4	12
13	Acute Hepatitis A and Hepatitis B Coinfection. ACG Case Reports Journal, 2021, 8, e00702.	0.2	2
14	Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. Clinical Gastroenterology and Hepatology, 2020, 18, 188-195.e4.	2.4	33
15	Downstaging to Liver Transplant. Clinics in Liver Disease, 2020, 24, 665-679.	1.0	0
16	Mortality in adults with chronic hepatitis B infection in the United States: a populationâ€based study. Alimentary Pharmacology and Therapeutics, 2020, 52, 382-389.	1.9	15
17	Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. American Journal of Gastroenterology, 2019, 114, 1753-1763.	0.2	17
18	Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?. AME Medical Journal, 2018, 3, 27-27.	0.4	6

#	Article	IF	CITATIONS
19	Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infectious Diseases, The, 2016, 16, 1409-1422.	4.6	123
20	Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection. Journal of Clinical Gastroenterology, 2014, 48, 548-552.	1.1	0